Nearly a decade in the making, University of Maryland, Baltimore pharmacy and medical experts were instrumental in a groundbreaking vote in November to remove a longstanding barrier to patients being prescribed clozapine, a medication used to treat schizophrenia and schizoaffective disorder.
A joint U.S. Food and Drug Administration (FDA) advisory committee — the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee — voted overwhelmingly on Nov. 19 to eliminate the risk evaluation and mitigation strategy (REMS) program for clozapine.
Read the full story on the School of Pharmacy's News Center.